
- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B -


Precision BioSciences, Inc.

- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B -


Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DTIL">DTIL</a>), a clinical stage gene editing company utilizing its novel proprietary ARCUS&#xAE; platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B trial during a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The ELIMINATE-B trial is evaluating PBGENE-HBV for the treatment of chronic hepatitis B. The EASL Congress 2026 is being held May 27-30, 2026, in Barcelona, Spain.


Title: First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV


Presenter: Man-Fung Yuen 
 Session: Late-Breaker Posters
 Abstract number: LB26-51656
 Presentation Number: LBP-043
 Date: May 27, 2026
 Time: 8:30 CEST


About PBGENE-HBV, A Viral Elimination Program


PBGENE-HBV is Precision's wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic Hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic Hepatitis B, cccDNA, while inactivating integrated HBV DNA. Elimination of cccDNA could result in HBV cure as cccDNA is the only source of infectious replication (HBV DNA). The ELIMINATE-B trial is investigating PBGENE-HBV at multiple dose levels across a number of administrations per dose level in patients with chronic Hepatitis B. PBGENE-HBV has been granted Fast Track designation by the FDA.


PBGENE-HBV is the only clinical stage program targeting the elimination of cccDNA leading to sustained loss of HBV DNA. The FDA has previously provided guidance that sustained loss of HBV DNA with or without loss of HBsAg is an approvable endpoint for chronic hepatitis B.


Further details on the trial can be found on Precision's website and on <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06680232&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=clinicaltrials.gov&amp;index=1&amp;md5=05989511a79b30d9dd024eac8c2f8edc" shape="rect">clinicaltrials.gov</a> identifier NCT06680232.


About Precision BioSciences, Inc.


Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS&#xAE; genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.precisionbiosciences.com&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=www.precisionbiosciences.com&amp;index=2&amp;md5=4c1a7dbe2ad2f95976b93809b952f233" shape="rect">www.precisionbiosciences.com</a>.


The ARCUS&#xAE; platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company's PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company's PBGENE-DMD program) and gene insertion (inserting DNA into gene to cause expression/add function).


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, expectations about operational initiatives, strategies, further development, or timing of additional updates or data releases of PBGENE-HBV, including new PBGENE-HBV clinical biopsy data; expectations around PBGENE-HBV being the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic Hepatitis B, cccDNA, while inactivating integrated HBV DNA; and the expectation that elimination of cccDNA could result in HBV cure as cccDNA is the only source of infectious replication (HBV DNA). . In some cases, you can identify forward-looking statements by terms such as "aim," "anticipate," "approach," "belief", "believe," "contemplate," "could," "design," "designed," "estimate," "expect," "goal," "intend," "look," "may," "mission," "plan," "possible," "potential," "predict," "project," "pursue," "should," "strive," "suggest," "target," "will," "would," or the negative thereof and similar words and expressions.


Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim "top-line" and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-K for the annual period ended December 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=8e11cb728cfa6523f1b007211440ce49" shape="rect">www.sec.gov </a>and the Investors page of our website under SEC Filings at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.precisionbiosciences.com%2F&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=investor.precisionbiosciences.com.&amp;index=4&amp;md5=3edd229e27664429a29bce315253055e" shape="rect">investor.precisionbiosciences.com.</a>


All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260422003618r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260422003618/en/" rel="nofollow">https://www.businesswire.com/news/home/20260422003618/en/</a>
Investor and Media Contact: 
 Naresh Tanna
 Vice President of Investor Relations
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:naresh.tanna@precisionbiosciences.com" shape="rect">naresh.tanna@precisionbiosciences.com</a>

DTIL

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

Positive Biopsy Data for Precision BioSciences' PBGENE-HBV at EASL 2026

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 - Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B -


Precision BioSciences, Inc.
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Precision BioSciences announced positive clinical data regarding PBGENE-HBV aimed at hepatitis B treatment at EASL Congress 2026. The data suggests effective cccDNA elimination, which may significantly influence the company&#039;s valuation and market position ahead of the presentation in May 2026.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Precision BioSciences presents positive biopsy data at EASL Congress 2026.</li><li>Data shows elimination of cccDNA in chronic hepatitis B patients with PBGENE-HBV.</li><li>This trial could be pivotal for hepatitis B treatment landscape.</li><li>PBGENE-HBV received FDA Fast Track designation, indicating its potential.</li><li>Presentation date is set for May 27, 2026, in Barcelona.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Precision BioSciences, Inc. (DTIL): Leading the field in curative hepatitis B treatment with unique gene editing technology.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news falls under &#039;Corporate Developments,&#039; highlighting significant advancements in Precision BioSciences&#039; therapeutic efforts. The promising clinical data could enhance investor confidence and market positioning in the gene editing sector.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Positive biopsy data could elevate DTIL&#039;s valuation dramatically.</li><li>FDA&#039;s Fast Track designation raises PBGENE-HBV&#039;s commercial viability.</li><li>Subsequent trials may attract more investment and partnerships.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>PBGENE-HBV is the first clinical program targeting cccDNA elimination.</li><li>Presentation scheduled for May 27, 2026, at EASL Congress.</li><li>Data demonstrates inactivation of HBV DNA in trial participants.</li><li>PBGENE-HBV received Fast Track designation by the FDA.</li><li>Previous FDA guidance identifies sustained HBV DNA loss as approvable.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Investors should consider accumulating DTIL shares in anticipation of positive market response post-EASL presentation.
 </section>
</section>



- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B -


Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DTIL">DTIL</a>), a clinical stage gene editing company utilizing its novel proprietary ARCUS&#xAE; platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B trial during a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The ELIMINATE-B trial is evaluating PBGENE-HBV for the treatment of chronic hepatitis B. The EASL Congress 2026 is being held May 27-30, 2026, in Barcelona, Spain.


Title: First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV


Presenter: Man-Fung Yuen 
 Session: Late-Breaker Posters
 Abstract number: LB26-51656
 Presentation Number: LBP-043
 Date: May 27, 2026
 Time: 8:30 CEST


About PBGENE-HBV, A Viral Elimination Program


PBGENE-HBV is Precision's wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic Hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic Hepatitis B, cccDNA, while inactivating integrated HBV DNA. Elimination of cccDNA could result in HBV cure as cccDNA is the only source of infectious replication (HBV DNA). The ELIMINATE-B trial is investigating PBGENE-HBV at multiple dose levels across a number of administrations per dose level in patients with chronic Hepatitis B. PBGENE-HBV has been granted Fast Track designation by the FDA.


PBGENE-HBV is the only clinical stage program targeting the elimination of cccDNA leading to sustained loss of HBV DNA. The FDA has previously provided guidance that sustained loss of HBV DNA with or without loss of HBsAg is an approvable endpoint for chronic hepatitis B.


Further details on the trial can be found on Precision's website and on <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06680232&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=clinicaltrials.gov&amp;index=1&amp;md5=05989511a79b30d9dd024eac8c2f8edc" shape="rect">clinicaltrials.gov</a> identifier NCT06680232.


About Precision BioSciences, Inc.


Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS&#xAE; genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.precisionbiosciences.com&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=www.precisionbiosciences.com&amp;index=2&amp;md5=4c1a7dbe2ad2f95976b93809b952f233" shape="rect">www.precisionbiosciences.com</a>.


The ARCUS&#xAE; platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company's PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company's PBGENE-DMD program) and gene insertion (inserting DNA into gene to cause expression/add function).


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, expectations about operational initiatives, strategies, further development, or timing of additional updates or data releases of PBGENE-HBV, including new PBGENE-HBV clinical biopsy data; expectations around PBGENE-HBV being the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic Hepatitis B, cccDNA, while inactivating integrated HBV DNA; and the expectation that elimination of cccDNA could result in HBV cure as cccDNA is the only source of infectious replication (HBV DNA). . In some cases, you can identify forward-looking statements by terms such as "aim," "anticipate," "approach," "belief", "believe," "contemplate," "could," "design," "designed," "estimate," "expect," "goal," "intend," "look," "may," "mission," "plan," "possible," "potential," "predict," "project," "pursue," "should," "strive," "suggest," "target," "will," "would," or the negative thereof and similar words and expressions.


Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim "top-line" and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-K for the annual period ended December 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=8e11cb728cfa6523f1b007211440ce49" shape="rect">www.sec.gov </a>and the Investors page of our website under SEC Filings at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.precisionbiosciences.com%2F&amp;esheet=54519802&amp;newsitemid=20260422003618&amp;lan=en-US&amp;anchor=investor.precisionbiosciences.com.&amp;index=4&amp;md5=3edd229e27664429a29bce315253055e" shape="rect">investor.precisionbiosciences.com.</a>


All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260422003618r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260422003618/en/" rel="nofollow">https://www.businesswire.com/news/home/20260422003618/en/</a>
Investor and Media Contact: 
 Naresh Tanna
 Vice President of Investor Relations
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:naresh.tanna@precisionbiosciences.com" shape="rect">naresh.tanna@precisionbiosciences.com</a>

Precision BioSciences announced positive clinical data regarding PBGENE-HBV aimed at hepatitis B treatment at EASL Congress 2026. The data suggests effective cccDNA elimination, which may significantly influence the company's valuation and market position ahead of the presentation in May 2026.

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News